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ABSTRACT
Prompt administration of anti-toxin reduces mortality following Corynebacterium diphtheriae
infection. Current treatment relies upon equine diphtheria anti-toxin (DAT), with a 10% risk of serum
sickness and rarely anaphylaxis. The global DAT supply is extremely limited; most manufacturers
have ceased production. S315 is a neutralizing human IgG1 monoclonal antibody to diphtheria
toxin that may provide a safe and effective alternative to equine DAT and address critical supply
issues. To guide dose selection for IND-enabling pharmacology and toxicology studies, we dose-
ranged S315 and DAT in a guinea pig model of diphtheria intoxication based on the NIH Minimum
Requirements potency assay. Animals received a single injection of antibody premixed with toxin,
were monitored for 30 days, and assigned a numeric score for clinical signs of disease. Animals
receiving  27.5 mg of S315 or  1.75 IU of DAT survived whereas animals receiving  22.5 mg of
S315 or  1.25 IU of DAT died, yielding a potency estimate of 17 mg S315/IU DAT (95% CI 16–21) for
an endpoint of survival. Because some surviving animals exhibited transient limb weakness, likely a
systemic sign of toxicity, DAT and S315 doses required to prevent hind limb paralysis were also
determined, yielding a relative potency of 48 mg/IU (95% CI 38–59) for this alternate endpoint. To
support advancement of S315 into clinical trials, potency estimates will be used to evaluate the
efﬁcacy of S315 versus DAT in an animal model with antibody administration after toxin exposure,
more closely modeling anti-toxin therapy in humans.
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Introduction
Diphtheria is a potentially fatal illness caused by infec-
tion with Corynebacterium diphtheriae and subsequent
elaboration of a potent exotoxin. Diphtheria toxin causes
tissue death at the site of production, mostly commonly
the respiratory tract, leading to the development of a
pathognomonic pharyngeal pseudomembrane and local
edema which can compromise the airway.1,2 Hematoge-
nous toxin dissemination can cause cranial nerve dys-
function, peripheral neuropathy and cardiotoxicity,
which is responsible for 50–75% of diphtheria deaths.3,4
Expanded access to vaccination with diphtheria toxoid
has decreased the incidence of diphtheria cases dramatically,
though diphtheria remains endemic in several countries.5-7
Over the last decade, 4,000–12,000 diphtheria cases have
been reported to the World Health Organization annually,
although the number of cases is likely underestimated and
deaths underreported.8 In addition, periodic outbreaks con-
tinue with recent epidemics in Haiti, Nigeria, South Africa,
Indonesia, and Laos and are often associated with high case
fatality rates (>10%) in resource-limited countries.9-14 Fatal
cases can also occur in developed countries among unvacci-
nated or undervaccinated populations, as illustrated with a
recent case from Spain.15 Sporadic epidemics will likely con-
tinue to occur due to disruption in national or regional vac-
cination programs from political instability, natural
disasters, or emerging infectious diseases; international
travel and relocation of susceptible persons also contribute
to the global risk of disease.
Morbidity and mortality due to diphtheria are greatly
reduced by prompt administration of anti-toxin antibodies
to neutralize diphtheria toxin and prevent further tissue
damage, in conjunction with antibiotic therapy to elimi-
nate C. diphtheriae and stop toxin production.16 Current
treatment relies upon equine-derived antibodies to diph-
theria toxin (Diphtheria Anti-Toxin, DAT) that carry the
risk of severe allergic reactions. The global supply of DAT
is extremely limited as many manufacturers have ceased
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production.15,17-19 In the United States, the standard of
care for suspected diphtheria is receipt of an unlicensed
DAT product provided under the federal expanded access
to investigational drugs program through a protocol spon-
sored by the Centers for Disease Control and Prevention.20
To address this unmet medical need, we are develop-
ing a human monoclonal antibody (mAb) to diphtheria
toxin to replace equine DAT for the treatment of diph-
theria. We previously identiﬁed a human IgG1 mAb
(designated S315) that binds to the toxin’s receptor bind-
ing domain and blocks the interaction with its putative
receptor, heparin-binding epidermal growth factor-like
growth factor.21 In preliminary animal experiments,
S315 improved the survival of animals exposed to diph-
theria toxin.21 In this report, we establish the relative
potency of the human anti-toxin mAb by determining
its neutralizing capacity relative to equine polyclonal
DAT standard in a guinea pig model of disease.
Although guinea pigs do not exhibit respiratory symp-
toms when subcutaneously challenged with diphtheria
toxin, they do express the cell surface receptor for the
toxin and are susceptible to the end organ effects of sys-
temic toxin (peripheral neuropathy, cardiomyopathy).22
A modiﬁed version of the National Institutes of Health
(NIH) Minimum Requirements assay designed for deter-
mination of potency of polyclonal DAT was utilized to
estimate the concentration of S315 mAb that provides
equivalent protection to DAT in guinea pigs subcutane-
ously injected with diphtheria toxin.23 We used this
model to evaluate the relative potency of a novel human
mAb to equine polyclonal DAT utilizing 2 different end-
points: overall survival at 30 d post-toxin exposure and
survival without hind limb paralysis.
Results
Overall survival from a lethal diphtheria toxin
challenge using DAT or S315
For the endpoint of survival following a lethal toxin chal-
lenge, a dose-dependent response was observed for both
the DAT and S315 mAb cohorts (Fig. 1). Among the
DAT-treated cohorts, all animals receiving  1.25 IU of
DAT died, with animals in the 2 lowest dose cohorts
dying earlier than those who received higher doses
(Fig. 2a). All animals receiving  1.75 IU of DAT sur-
vived. Variable survival was observed in cohorts receiving
1.5 IU – 1.6 IU DAT; in the ﬁrst experiment, 5 of 5 ani-
mals receiving 1.5 IU DAT survived while in the second
experiment 3 of 5 animals receiving 1.5 IU of DAT sur-
vived. All 5 animals treated with 1.55 IU of DAT survived,
while one of the 5 animals treated with 1.6 IU of DAT
died. For the S315 cohorts, no animals receiving doses 
22.5 mg survived, and a dose-dependent effect on time of
death was observed (Fig. 2b). All animals receiving 
27.5 mg of mAb survived. Variable survival was observed
for the 25 mg dose; 1 of 5 animals receiving 25 mg of mAb
survived in the ﬁrst experiment while in the second exper-
iment, 4 of 5 animals receiving 25mg of mAb survived.
Using a logistic model, the calculated half maximal
effective dose (ED50) for overall survival was 25.0 mg for
mAb (95% CI: 23.4, 26.5) and 1.45 IU for DAT (95% CI:
1.21, 1.50), yielding a relative potency estimate of 17 mg
mAb/IU DAT (95% CI: 16, 21).
Survival without hind limb paralysis using DAT or
S315
Some of the surviving animals in the DAT or S315 dosed
cohorts developed transient limb weakness, described
historically in this model and attributed to toxin-medi-
ated peripheral neuropathy.24 Therefore, we sought to
determine the doses of DAT and mAb required to pre-
vent a systemic sign of toxicity, using hind limb paralysis
(clinical score D 4) as a marker of end-organ damage.
Among the DAT-treated cohorts, a similar dose-
dependent response was observed (Fig. 1a). At DAT
doses equal or above 1.75 IU, all animals survived with-
out hind limb paralysis. Variability was observed again
for the animals dosed with 1.5 IU of DAT; 2 of the 5 sur-
viving animals in the ﬁrst experiment exhibited transient
hind limb weakness, while in the second experiment,
none of the surviving animals in the 1.5 IU cohort exhib-
ited hind limb paralysis (Fig. 3a). The proportion of ani-
mals surviving without hind limb paralysis was identical
to the overall survival percentage for the 1.55 IU cohort
(100%) and the 1.6 IU cohort (80%).
For the mAb-treated animals, a higher dose was
required to observe survival without hind limb paralysis
(Fig. 1b). All ﬁve animals in the 27.5 mg and 37.5 mg
cohorts developed transient limb weakness but survived
(Fig. 3b). As the dose of S315 increased, the onset of
paralysis was delayed and a smaller proportion of surviv-
ing animals in each cohort exhibited limb weakness. All
ﬁve animals in the 100 mg mAb group survived without
hind limb paralysis.
The calculated ED50 for survival without hind paraly-
sis was 67.4 mg for mAb (95% CI 53.4, 80.2) and 1.42 IU
for DAT (95% CI 1.25, 1.52). The relative potency of
S315 to DAT using this endpoint was 48 mg mAb/IU
DAT (95% CI: 38, 58).
Weight gain following diphtheria toxin challenge
Average baseline weights for each dosing cohort ranged
from 249 to 258 g in the DAT group and from 253 to
VIRULENCE 661
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272 g in the mAb group and were not signiﬁcantly differ-
ent between dosing cohorts (ANOVA test, p D 0.87 for
the DAT group and p D 0.34 for the mAb group).
For the DAT treatment groups, mean weight gains at
Day 7 (Week 1) ranged from 39 to 51 g andwere not signif-
icantly different among dose levels (p D 0.54, Chi-square
test using GEE model). The mean weight in the dynamic
cohorts of survivors continued to increase (ranged from
31.0 to 43.9 g per week) for all but the 1.25 IU group, whose
mean weight dropped 10.6 g during Week 2, with all ani-
mals subsequently euthanized for beingmoribund (clinical
score D 5) by Day 12. At Day 28 (Week 4), estimated
mean weight gains from baseline were similar among the
1.5 IU, 1.55 IU, 1.75 IU and 2.0 IU dosing cohorts (152–
Figure 1. Percent survival following receipt of ﬁxed diphtheria toxin dose pre-mixed with varying amount of antibody by outcome for
DAT and mAb treated cohorts. The proportion of animals surviving at each antibody dose is shown in the solid bars and the proportion
surviving without symptoms of hind limb paralysis is shown in the hatched bars. The number of animals (n) evaluated in each cohort is
noted on the graph. The results for cohorts receiving equine diphtheria anti-toxin (DAT) are shown in panel A and those for cohorts
given S315 human monoclonal antibody to diphtheria toxin are shown in panel B.
662 H. L. SMITH ET AL.
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163 g, p D 0.44), but it was signiﬁcantly higher for the
2.5 IU cohort (183 g, p D 0.01) and signiﬁcantly lower for
the 1.6 IU cohort (133 g, pD 0.01).
For the mAb treatment groups, mean weight gains at
Day 7 (Week 1) were similar among all but the 27.5 mg
cohort (31–49 g, pD 0.15); it was signiﬁcantly lower for the
27.5 mg cohort (23.5 g, p D 0.03). The mean weight in the
dynamic cohorts of survivors continued to increase (ranged
from 10.7 to 43.8 g per week) for all except for the 8 mg
cohort, whose mean weight dropped 2.5 g during Week 2,
with all animals euthanized by Day 14 for being moribund,
and the 14 mg cohort whose mean weight at Week 2 was
not estimable. At Day 28 (Week 4), estimated mean weight
gains from baseline signiﬁcantly differed among the 25 to
100mg dosing cohorts, but were similar between the 25 and
27.5 mg cohorts (106–117 g, pD 0.2), between the 37.5 and
75 mg cohorts (140–143 g, p D 0.74) and between the 50
and 100mg cohorts (161–176 g, pD 0.06)
Figure 2. Survival over time by antibody cohort following diphtheria toxin challenge. The proportion of animals surviving over the 30-
day study period by study day following receipt of toxin-antibody mixture is shown for equine diphtheria anti-toxin (DAT) dosing
cohorts in panel A and for S315 human monoclonal antibody dosing cohorts in panel B.
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Discussion
We evaluated the potency of a human mAb to diph-
theria toxin (S315) relative to a standard preparation
of equine polyclonal DAT in order to quantify the
biologic activity of the mAb in an animal model of
diphtheria intoxication. We used an assay that is
employed to assign potency of diphtheria anti-toxin
preparations, modiﬁed with an extended period of
observation to allow for greater differentiation of dose
effects and evaluation of delayed effects of diphtheria
toxin.
Relative potency is the biologic activity of a substance
compared to a standard. Equine DAT is a polyclonal
antibody preparation derived from horses hyperimmu-
nized with toxin. Similar to other polyclonal antibody
Figure 3. Survival over time without hind limb paralysis by antibody cohort following diphtheria toxin challenge. The proportion of ani-
mals surviving without hind limb paralysis over the 30-day study period by study day following receipt of toxin-antibody mixture is
shown for equine diphtheria anti-toxin (DAT) dosing cohorts in panel A and S315 human monoclonal antibody dosing cohorts in
panel B.
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products used clinically, DAT contains a variety of
immunoglobulins, most of which are not speciﬁc for
diphtheria toxin. In addition, the amount and composi-
tion of antibodies which are speciﬁc to diphtheria toxin
will vary among product lots as the antibody repertoire
differs both between blood donors as well as between dif-
ferent sampling timepoints in the same donor. Therefore,
clinical grade polyclonal antibody products, such as
DAT, hepatitis B immunoglobulin, and human rabies
immunoglobulin, are quantiﬁed by an assignment of
units of neutralizing activity per volume of serum or
plasma (IU/mL) relative to a standard preparation rather
than by protein concentration. In contrast, a monoclonal
antibody product consists of one antibody molecule with
singular speciﬁcity whose protein concentration can be
directly measured by ultraviolet light absorbance. The
neutralizing activity contained in one microgram of puri-
ﬁed mAb can therefore be determined by evaluating the
mAb relative to a standard. The FDA diphtheria anti-
toxin standard is a polyclonal preparation quantiﬁed in
international units (IUs); therefore, the relative potency
of the S315 mAb is expressed as micrograms of the
monoclonal antibody per one unit of the polyclonal stan-
dard (mg/IU).
When overall survival was used as the clinical end-
point of the potency assessment, a dose response with
regard to time of death was observed with more rapid
onset in the cohorts receiving lower doses of DAT or
mAb, though there was insufﬁcient power for a formal
time-to-event analysis. Interestingly, a steep threshold
effect was observed with progression from 0% survival to
100% survival over a narrow dose range: 22.5 mg-
27.5 mg for S315 mAb and 1.25–1.75 IU for DAT.
Given that some of the surviving animals in both the
mAb and the DAT groups exhibited transient hind limb
weakness, a likely manifestation of diphtheria toxin’s
effects on peripheral nerves,25,26 we performed a second
analysis with an endpoint of survival without hind limb
paralysis. For the DAT group, the dose-response curve
looked similar to the overall survival endpoint; however,
some surviving animals in the 1.5 IU DAT cohort devel-
oped transient paralysis. There was a pronounced
threshold effect, with all animals receiving  1.75 IU
DAT surviving without paralysis. For the mAb-treated
group, a more linear dose response was observed with
this endpoint. Transient paralysis was observed in some
animals in the cohorts with 100% overall survival, with
the proportion of animals exhibiting hind limb weakness
decreasing with higher mAb doses. All animals receiving
100 mg of mAb survived without developing paralysis.
The doses observed for full protection from toxin-
induced symptoms in this study are higher than those
reported previously.21 Smaller sample size and more
limited daily observation in the preliminary studies may
explain these differences.
While analysis of hind limb paralysis in survivors
appears to offer additional insight into the neutralization
of toxin by different doses of anti-toxin antibody, there
was no differential effect on overall health with respect
to weight gain except in animals progressing rapidly
toward death. For the cohorts with surviving animals,
the mean weight gain was similar to a reference set of
data (n D 1641) for the same strain animals receiving
irrelevant protein only (tetanus toxoid) housed under
equivalent conditions, that showed mean weekly weight
gains of 46.2 g [SD 13.2] (unpublished data). Thus, anal-
yses of weight or growth appear likely to be less informa-
tive than careful observation of locomotor function in
guinea pig acute diphtheria intoxication models.
The DAT ED50 for an endpoint of survival without
paralysis (1.42 IU) was similar to the ED50 for the overall
survival endpoint (1.45 IU). For the mAb-treated ani-
mals, a higher dose was required to protect from hind
limb weakness, with the ED50 increasing from 25.0 mg
for the overall survival endpoint to 67.4 mg using survival
without paralysis as the endpoint. The greater magnitude
of change for the mAb compared to DAT for these 2
endpoints is challenging to interpret, as dosing for the
mAb was based on measured protein concentrations
(mg/mL) whereas DAT doses were unit measures of
functional activity (IU/mL). The dose-response curves of
an anti-diphtheria toxin monoclonal antibody compared
to polyclonal antibody were not parallel under these
experimental conditions. The use of a guinea pig model
with a lower toxin dose may allow a more linear dose
response for survival endpoints to be established for
both types of antibody preparations.
These potency estimates for 2 different clinical end-
points provide a foundation for further development of
S315. Since the treatment of diphtheria is empirical dos-
ing of equine DAT based on the clinical condition of the
patient and there are no human data correlating serum
concentrations of diphtheria anti-toxin with clinical efﬁ-
cacy, dose selection of a monoclonal antibody to diph-
theria toxin for evaluation in clinical trials will be
facilitated by the relative potency estimates established in
animal models. Given the variation in the point estimates
of relative potency depending on the endpoint analyzed
in a modiﬁed NIH Minimum Requirements assay, we
plan to establish a guinea pig model of anti-toxin admin-
istration after diphtheria toxin exposure to rigorously
evaluate the potency estimates. This model will more
closely mimic the timing of anti-toxin treatment in
humans and will enable use of a lower dose of toxin,
potentially allowing a more linear dose-response curve
to be established for DAT. Results from this post-
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exposure treatment model will assist us in determining a
protective therapeutic dose of S315 relative to DAT and
allow us to investigate the correlation between serum
neutralizing titer and protection in the toxin challenge
model. These data, in conjunction with ongoing efforts
to quantify the serum neutralizing activity achieved fol-
lowing DAT dosing in patients with suspected diphthe-
ria, will further reﬁne an appropriate range for dosing
S315 in a Phase 1 clinical trial.
Materials and methods
Laboratory animals
All experiments were performed with the approval of the
University of Massachusetts Medical School Institutional
Animal Care and Use Committee and in accordance
with National Institute of Health Guidelines. Female
Hartley guinea pigs (weight 240–280 g) were obtained
from Charles River Laboratories (Wilmington, MA) and
acclimated to our facility for 1 week prior to study
intervention.
Diphtheria toxin
K561, a standardized diphtheria toxin reagent prepared
from a crude ﬁltrate of vaccine strain C. diphtheriae cul-
ture (MassBiologics, Boston, MA), was utilized in these
studies. Qualiﬁcation was performed to determine the
dilution of toxin K561 that, when pre-mixed with 1 IU
of DAT (Food and Drug Administration DAT standard,
lot #F4509), caused death of a guinea pig between 40 and
96 hours. This dose, deﬁned as the “LC dose” of diphthe-
ria toxin in the NIH Minimum Requirements,23 con-
tained 2 Lf of toxin (an Lf or “limit of ﬂocculation” unit
is deﬁned by immunoprecipitation of antibody and anti-
gen)27 or 102 minimum lethal doses (MLD, deﬁned as
the lowest dose of toxin that is lethal to a 200–300 g
guinea pig between 72 and 96 hours after sub-cutaneous
administration). A control group of 2 guinea pigs receiv-
ing 1 IU of DAT pre-mixed with toxin was included in
each experiment to conﬁrm toxin activity.
Antibodies
Equine diphtheria anti-toxin standard was obtained from
the FDA (lot # F4509). The human mAb S315 is an IgG1
antibody originally cloned from a human B cell. Details
of the isolation, production and preparation of the
recombinant molecule were previously described in
detail.21
Animal model of lethal challenge with diphtheria
toxin
After acclimation, animals were divided into dosing
cohorts of 5 animals each. A protocol-speciﬁed dose of
DAT or S315 was pre-mixed with the ﬁxed dose of K561
toxin and incubated at room temperature for at least one
hour prior to injection. Each animal received a single
3.0 mL subcutaneous injection of toxin/anti-toxin mix-
ture on Day 0. This approach was based on the NIH
Minimum Requirements for determination of potency of
diphtheria anti-toxin preparations.23 The NIH Bureau of
Biologic Standards was previously the agency responsible
for regulating biologics; it has now become the Center
for Biologics Evaluation and Research (CBER) which is
part of the FDA. The NIH Minimum Requirements are
standards issued by this agency to govern the measure-
ment of diphtheria toxin neutralizing activity and remain
in use today. The assay was modiﬁed to extend the
period of observation to 30 d (from the standard
96 hours) to allow for greater differentiation of dose
effects and for evaluation of signs of toxin-induced end-
organ damage occurring up to 30 d after toxin exposure.
Animals were observed daily for signs of diphtheria
intoxication and weights were obtained weekly as a mea-
sure of overall health status. A numeric scoring system
of clinical signs was assigned a priori: No symptoms D 0;
Scruffy fur D 1; Lethargic D 2; Dehydrated D 3; Drag-
ging one or both hind legs D 4; Moribund D 5; Death D
6. Moribund animals or those with > 20% weight loss
from baseline were euthanized.
In order to generate a dose-response curve which
could be utilized to estimate relative potency, DAT and
monoclonal antibody doses were selected that were likely
to produce 0–20% protection in the lowest dosed cohort
to 80–100% protection in the highest dosed cohort. As
the dose of toxin utilized in this animal model consis-
tently causes death between 40 hrs and 96 hrs when pre-
mixed with 1 IU of DAT, DAT doses of 1.25 IU to
1.5 IU were evaluated in an initial experiment. Initial
doses of S315 ranging from 8 mg to 25 mg were evaluated
based on previous study results.21 A second experiment
was performed with a higher dose range for DAT (1.5 IU
to 2.5 IU) and for S315 (25 mg to 100 mg) to determine
relative potency for an endpoint of survival without hind
limb paralysis. The 1.5 IU DAT dose and the 25 mg S315
dose were repeated in the second study to bridge results
between the 2 experiments.
Statistical analyses
The percentage of animals in each cohort that survived
for 30 d post-toxin exposure or survived for 30 d without
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signs of hind limb paralysis was calculated. Euthanized
animals were counted as deaths in the survival analyses.
Logistic analyses were performed in SAS IML to calculate
the half maximal effective dose (ED50) for DAT and
S315; the SAS IML code was validated against the origi-
nal publication.28 The ED50 values were used to estimate
the relative potency of S315 (in mg) to DAT (in units).
Fieller’s Theorem was used to calculate the 95% ﬁducial
limits around the ED50 values and relative potency.
29
Baseline weights were examined among the dosing
cohorts using ANOVA tests for the 2 antibody treat-
ments. Partially conditional regression models were used
to estimate weekly weight changes from the baseline at
different time points up to 28 d among the surviving sub-
jects.30 For each antibody group, the model assumed an
initial weight change at Day 7 and a linear weight change
slope in the dynamic cohorts of survivors for each dose
level and the parameters were estimated by generalized
estimating equation (GEE).
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